Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome
Authors:
- 15 April 2025
- journal article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 25 (5) , 467-471
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trialNature Communications, 2025
- Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19–induced and/or aggravated ME/CFSMolecular Therapy, 2025
- Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort studyThe Lancet Regional Health - Europe, 2024
- Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19Nature Communications, 2024
- Long COVID science, research and policyNature Medicine, 2024
- A causal link between autoantibodies and neurological symptoms in long COVIDmedRxiv, 2024
- Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposiumAutoimmunity Reviews, 2023
- Intravenous immunoglobulins in the treatment of post‐COVID: A case–control studyJournal of Internal Medicine, 2022
- Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum StudyMultiple Sclerosis and Related Disorders, 2022
- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet Neurology, 2021